Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their existing collaboration to provide Regeneron with rights to develop in vivo CRISPR/Cas9-based therapeutic targets and for the two firms together to develop treatments for hemophilia A and B. Read More
EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer. Read More
AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity and more. Read More
Novasep, Lysogene partner for gene therapy
Novasep and Lysogene announced that the parties have inked an agreement for the development and manufacturing of an adeno-associated viral vector-based gene therapy drug candidate (LYS-GM101) for the treatment of GM1 gangliosidosis, a neuronopathic lysosomal storage disorder. Read More
NIIMBL funds new biopharmaceutical manufacturing projects
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) announced that it is funding 14 new projects in technology, workforce development, and the Global Health Fund initiative, amounting to approximately $10 million. Read More
Cellect to develop stem cell therapy for COVID-19
Cellect Biotechnology has inked an agreement with international collaborators to develop a stem cell therapy for COVID-19 disease. Read More
Boehringer Ingelheim acquires Northern Biologics
Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline. Read More
Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting on May 14. Read More
Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy. Read More
Bio-Techne releases new T-cell activation kit
Bio-Techne has released a new kit for cell and gene therapy manufacturing called GMP Cloudz Human T Cell Activation. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter